Rxo (RXO) Change in Accured Expenses (2022 - 2026)

Rxo (RXO) has 5 years of Change in Accured Expenses data on file, last reported at -$36.0 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 140.0% year-over-year to -$36.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.0 million (down 123.46% YoY) and the FY2025 annual result came in at $2.0 million, down 98.29% from the prior year.
• Change in Accured Expenses retreated to -$36.0 million in Q1 2026, from $75.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $102.0 million in Q4 2024 to a low of -$60.0 million in Q2 2023.
• A 5-year average of $2.6 million and a median of $1.0 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses slumped 957.14% — and 2024, when it surged 2000.0%.
• Tracing RXO's Change in Accured Expenses over 5 years: stood at -$17.0 million in 2022, then grew by 29.41% to -$12.0 million in 2023, then jumped by 950.0% to $102.0 million in 2024, then decreased by 26.47% to $75.0 million in 2025, then plunged by 148.0% to -$36.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$36.0 million (Q1 2026), $75.0 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.